BRCA1 (n (%)) | BRCA2 (n (%)) 6174delT | Total positive | Total (n) | ||
---|---|---|---|---|---|
185delAG | 5382insC | ||||
*Ashkenazi Jewish male controls 50 years and above without history of prostate cancer. | |||||
†p<0.05. | |||||
Israeli Prostate Study | 14 (1.49) | 2 (0.21) | 14 (1.49) | 30 (3.19) | 940 |
WAS* | 6 (0.7) | 2 (0.2) | 5 (0.6) | 13 (1.49) | 872 |
OR | 2.18 | 0.93 | 2.62 | 2.18† | |
95% CI | 0.78 to 6.96 | 0.07 to 12.82 | 0.89 to 9.34 | 1.09 to 4.43 | |
Israeli Prostate Study | 14 (1.49) | 2 (0.21) | 14 (1.49) | 30 (3.19) | 940 |
MECC* | 2 (0.42) | 1 (0.21) | 5 (1.06) | 8 (1.69) | 472 |
OR | 3.55 | 1.00 | 1.41 | 1.91 | |
95% CI | 0.80 to 15.70 | 0.09 to 11.1 | 0.50 to 3.94 | 0.87 to 4.20 | |
Israeli Prostate Study | 14 (1.49) | 2 (0.21) | 14 (1.49) | 30 (3.19) | 940 |
WAS+MECC* | 8 (0.59) | 3 (0.22) | 10 (0.74) | 21 (1.56) | 1344 |
OR | 2.52 | 0.22 | 2.02 | 2.08† | |
95% CI | 1.05 to 6.04 | 0.16 to 5.72 | 0.16 to 5.72 | 0.16 to 5.72 |